



# Pharmaids Pharmaceuticals Limited

PPL/BSE/Q1/38/17-18

Date: 21.08.2017

To  
The Corporate Relation Department  
The Bombay Stock Exchange Ltd.  
Floor 25, P J Towers,  
Dalal Street,  
Mumbai - 400 001.

Dear Sir,

**Sub:- Submission of Auditors Limited Review Report -un-Audited  
Result for the Quarter ended 30<sup>th</sup> June, 2017 - Reg.**

**Ref:- Scrip Code 524572. Compliance of Clause 41 of the Listing Agreement**

\*\*\*\*\*

Herewith we are enclosing the Auditors Limited Review Report issued on the Financials for the 1<sup>st</sup> Quarter ended 30<sup>th</sup> June, 2017 - Reg.


This is for your information & records in compliance of clause 41 of Listing Agreement.

Kindly acknowledge the receipt.

Thanking you

**For Pharmaids Pharmaceuticals Limited**

Compliance Officer  
Encl :- As above





**Name of the Company PHARMAIDS PHARMACEUTICALS LIMITED**  
**Statement of Profit and Loss for the period ended 30th June, 2017**

Rs. In lakhs

	Particulars	Note No.	Qtr. Ended Unaudited 30.06.2017	Qtr. Ended Audited 31.03.2017	Qtr. Ended Unaudited 30.06.2016	Year Ended Audited 31.03.2017
I	Revenue From Operations		19.58	25.79	34.2	120.25
II	Other Income		0	0.97	0.04	1.01
-III	Total Income (I+II)		19.58	26.76	34.24	121.26
IV	<b>EXPENSES</b>		23.86	-5.81	3.19	64.49
	Cost of materials consumed		2.63	20.69	10.23	0
	Purchases of Stock-in-Trade			2.48	7.95	2.95
	Changes in inventories of finished goods, Stock-in -		3.51	1.91	5.98	16.63
	Employee benefits expense		0.02	0.05	1.37	4.01
	Finance costs			0.49	1.96	6.37
	Depreciation and amortization expense		7.98	41.84	5.41	70.53
	Other expenses		38	61.65	36.09	164.98
	Total expenses (IV)		-18.42	-34.89	-1.85	-43.72
V	Profit/(loss) before exceptional items and tax (III- IV)			51.97	0.04	51.97
VI	Exceptional Items					
VII	Profit/(loss) before tax (V+VI)		-18.42	17.08	-1.81	8.25
VIII	Tax expense:		0	0	0	0
	(1) Current tax		0	-2.72	0	-2.72
	(2) Deferred tax		-18.42	19.8	-1.81	10.97
IX	Profit (Loss) for the period from continuing operations		0	0	0	0
X	Profit/(loss) from discontinued operations		0	0	0	0
XI	Tax expense of discontinued operations		0	0	0	0
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)		-18.42	19.8	-1.81	10.97
XIII	Profit/(loss) for the period (IX+XII)					
XIV	Other Comprehensive Income A (i) Items that will not be reclassified to profit or loss (ii) Income tax relating to items that will not be B (i) Items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss					
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period)					
XVI	Earnings per equity share (for continuing operation):		-0.54	0.5	-0.05	0.32
	(1) Basic		-0.54	0.5	-0.05	0.32
	(2) Diluted					0
XVII	Earnings per equity share (for discontinued operation):					
	(1) Basic					
	(2) Diluted					0
XVIII	Earnings per equity share (for discontinued & continuing operations)					
	(1) Basic					
	(2) Diluted					

**Notes:**

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 21st August, 2017. 2. The Un-Audited Financial Results for the Quarter ended 30th June, 2017 have been prepared and reviewed by the Statutory Auditors in pursuance of Schedule III of Companies Act, 2013. 3. The figures of the previous year/periods have been re-grouped/re-classified, whenever necessary, for the purpose of comparison. 4) The company operates in a single segment and the results pertain to a single segment. i.e., drug formulation only 5) Provision for Income Tax and Deferred Tax will be made at the end of the Financial year.

Place : Hyderabad  
Date : 21-08-2017

For PHARMAIDS PHARMACEUTICALS LIMITED  
**DR. GHISULAL JAIN**  
MANAGING DIRECTOR







**RAKESH S JAIN & ASSOCIATES**  
CHARTERED ACCOUNTANTS

B. Ramesh Kumar (Mob) : +91-9849025641  
E-mail : rsjainassociates@rediffmail.com

14-6-191, Nagar Khana, Begum Bazar,  
Hyderabad - 500 012. (T.S.) INDIA.

Date :

### LIMITED REVIEW REPORT

To  
The Board of Directors,  
M/s Pharmaids Pharmaceuticals Limited,  
Hyderabad.

We have reviewed the accompanying statement of unaudited financial results of **Pharmaids Pharmaceuticals Limited** for the Quarter ended 30<sup>th</sup> June, 2017. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

**Management has informed to us being quarterly closing, the company has not accounted for taxes on income i.e. Deferred Tax and Income Tax, the same will be considered at the time of year end.**

Based on our review conducted as above and subject to the points mentioned above, nothing has come to our attention that causes us to believe that the accompanying statements of unaudited financial results prepared in accordance with applicable Accounting Standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI(Listing obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **RAKESH S. JAIN AND ASSOCIATES**  
Chartered Accountants  
Firm Registration No. 010129S

